TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7905660

Group type: EXPERIMENTAL
Intervention: Ebrotidine (800 mg) plus ASA (500 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo plus ASA (500 mg)
Number of subjects: 10
Study: 3641787

Group type: EXPERIMENTAL
Intervention: Fosfomycin plus ampicillin (4 g fosfomycin every 8 h and 1 g ampicillin every 6 h)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Gentamicin plus ampicillin (80 mg gentamicin every 8 h and 1 g ampicillin every 6 h)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fosfomycin plus ampicillin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Gentamicin plus ampicillin
Number of subjects: 32
Study: 31880993

Group type: EXPERIMENTAL
Intervention: 0.2 g/kg BW oyster meat preload
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.1 g/kg BW oyster meat preload
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0 g/kg BW (control)
Number of subjects: 20
Study: 30409497

Group type: EXPERIMENTAL
Intervention: Weight Bearing (WB) Merchant view
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-Weight Bearing (NWB) view
Number of subjects: 0
Study: 26732282

Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH; 3450 m terrestrial altitude)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (NH; 3450 m simulated altitude)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normobaric normoxia (NN)
Number of subjects: 16
Study: 24504222

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EN)
Number of subjects: 120
Study: 22425161

Group type: EXPERIMENTAL
Intervention: Reloading multiband ligator with SD-c conductor
Number of subjects: 460

Group type: COMPARATOR
Intervention: Disposable ligator (control group)
Number of subjects: 460
Study: 20670420

Group type: EXPERIMENTAL
Intervention: Error-Reducing (ER) training
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Error-Enhancing (EE) training
Number of subjects: 8

Group type: COMPARATOR
Intervention: Both ER and EE training
Number of subjects: 8
Study: 18312804

Group type: COMPARATOR
Intervention: Staff-directed intervention
Number of subjects: 8727

Group type: EXPERIMENTAL
Intervention: Program Champion-directed intervention
Number of subjects: 8727

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8727
Study: 16230259

Group type: EXPERIMENTAL
Intervention: 300 mg irbesartan
Number of subjects: 4100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4100

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 4100
Study: 12032008

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 26
Study: 9512880

Group type: EXPERIMENTAL
Intervention: Enrolled in vaccine trial
Number of subjects: 429

Group type: COMPARATOR
Intervention: Not enrolled in vaccine trial
Number of subjects: 429
Study: 7879333

Group type: EXPERIMENTAL
Intervention: Hematuria home screening
Number of subjects: 1575

Group type: COMPARATOR
Intervention: Control group (unscreened cases)
Number of subjects: 1575

Group type: COMPARATOR
Intervention: Control group (men solicited but declined screening)
Number of subjects: 1575
Study: 2374829

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (n = 39, 60-70% HRR)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Low intensity exercise (n = 33, 30-40% HRR)
Number of subjects: 72
Study: 623136

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide alone (with possible addition of alpha methyldopa or propranolol)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide alone
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Combination therapy (hydrochlorothiazide + alpha methyldopa)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 300
Study: 31265476

Group type: EXPERIMENTAL
Intervention: Supervised home-based physical exercise (2-3 sessions/week for 2-3 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Self-administered exercise program
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Supervised home-based physical exercise
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard care group (control)
Number of subjects: 23
Study: 28155175

Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg/day
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study: 25842725

Group type: EXPERIMENTAL
Intervention: Qingrehuatan decoction (QRHT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (healthy males)
Number of subjects: 12
Study: 23260101

Group type: EXPERIMENTAL
Intervention: Gastric tube feeding
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intravenous fluids
Number of subjects: 51
Study: 20884007

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5, 10, or 20 mg) for a mean period of 29 weeks
Number of subjects: 29
Study: 19349630

Group type: EXPERIMENTAL
Intervention: Triple-combination pharmacotherapy (nicotine patch, nicotine oral inhaler, and bupropion ad libitum)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Nicotine patch alone for a standard 10-week course
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Triple-combination pharmacotherapy
Number of subjects: 127

Group type: COMPARATOR
Intervention: Nicotine patch alone
Number of subjects: 127
Study: 17116766

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 30 mg
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 40 mg
Number of subjects: 873

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg
Number of subjects: 873
Study: 14985222

Group type: EXPERIMENTAL
Intervention: Zinc alone (10 mg Zn; n = 81)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Zinc plus vitamins and minerals (Zn+VM; n = 82)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo (n = 83)
Number of subjects: 246
Study: 11371689

Group type: EXPERIMENTAL
Intervention: Abacavir (ABC) 600 mg twice daily
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (ABC-matched)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Number of subjects: 105
Study: 9682356

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 47
Study: 7991312

Group type: EXPERIMENTAL
Intervention: Increased response velocity
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Decreased range of movement
Number of subjects: 25
Study: 2647807

Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pleasant imagery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Analgesic imagery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pain discussion (attention control)
Number of subjects: 40
Study: 768962

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 35
Study: 31744119

Group type: EXPERIMENTAL
Intervention: Dark Chocolate (DC) intake group (n = 10)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cacao-free white chocolate (WC) intake group (n = 8)
Number of subjects: 18
Study: 30269035

Group type: EXPERIMENTAL
Intervention: Cranberry diet (animal-based diet plus 30 g/day freeze-dried whole cranberry powder)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control diet (animal-based diet plus 30 g/day placebo powder)
Number of subjects: 11
Study: 26434651

Group type: EXPERIMENTAL
Intervention: Adjunctive full-mouth intensive removal of subgingival dental plaque biofilms with scaling and root planning (group 2)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard cycle of supragingival mechanical scaling and polishing (group 1)
Number of subjects: 109
Study: 25082595

Group type: EXPERIMENTAL
Intervention: Granisetron (40 μg/kg)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 21572334

Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 42
Study: 20362507

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg intravenously every 3 weeks for 1 year)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No zoledronic acid (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 120
Study: 17327378

Group type: EXPERIMENTAL
Intervention: PPARgamma agonist (rosiglitazone)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PPARalpha agonist (fenofibrate)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Combination of metyrapone and RU38486 (glucocorticoid blockade)
Number of subjects: 33
Study: 15642026

Group type: EXPERIMENTAL
Intervention: Resective surgery and modification of surface topography (test group)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Resective surgery only (control group)
Number of subjects: 17
Study: 12395217

Group type: EXPERIMENTAL
Intervention: Water dispersible beta-carotene powder (7.2 mg/d)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Water dispersible beta-carotene powder (21.6 mg/d)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carrot juice-based drink (6 mg/d)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carrot juice-based drink (18 mg/d)
Number of subjects: 8
Study: 10219465

Group type: EXPERIMENTAL
Intervention: High dose benfotiamine (4 x 2 capsules/day, = 320 mg benfotiamine/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Medium dose benfotiamine (3 x 1 capsules/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Monotherapy with benfotiamine (3 x 1 tablets/day, = 150 mg benfotiamine/day)
Number of subjects: 36
Study: 7727315

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU), 700 mg/m2
Number of subjects: 332

Group type: COMPARATOR
Intervention: No systemic therapy
Number of subjects: 332
Study: 1895746

Group type: EXPERIMENTAL
Intervention: Silicon oil tamponade
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SF6-gas tamponade
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BSS or air tamponade
Number of subjects: 30
Study: 7273700

Group type: EXPERIMENTAL
Intervention: Amitriptyline (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Doxepin (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Desipramine (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Imipramine (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nortriptyline (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6303673

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg in the morning and placebo in the evening (Group I)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg twice daily (Group II)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (Group III)
Number of subjects: 31
Study: 30507711

Group type: EXPERIMENTAL
Intervention: Conventional-dose hormone therapy
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Low-dose hormone therapy
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Conventional-dose hormone therapy (in women with a history of venous thrombosis)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Placebo (in women with a history of venous thrombosis)
Number of subjects: 342
Study: 29358120

Group type: EXPERIMENTAL
Intervention: 8-week intervention based on profound stress attunement
Number of subjects: 733
Study: 27806355

Group type: EXPERIMENTAL
Intervention: Lowering dialysate calcium concentration to 1.25 mmol/l
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group with dialysate calcium concentration at 1.5 mmol/l
Number of subjects: 2
Study: 25372006

Group type: EXPERIMENTAL
Intervention: home-based modified constraint-induced movement therapy (mCIMT)
Number of subjects: 22
Study: 22506894

Group type: EXPERIMENTAL
Intervention: Articulatory suppression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Foot-tapping condition
Number of subjects: 0
Study: 21060040

Group type: EXPERIMENTAL
Intervention: 400 IU of vitamin E on alternate days
Number of subjects: 11545

Group type: EXPERIMENTAL
Intervention: 500 mg of vitamin C daily
Number of subjects: 11545

Group type: COMPARATOR
Intervention: Placebo for vitamin E
Number of subjects: 11545

Group type: COMPARATOR
Intervention: Placebo for vitamin C
Number of subjects: 11545
Study: 17580445

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 15510184

Group type: EXPERIMENTAL
Intervention: Apomorphine SL (3 mg, four tablets)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 12206276

Group type: EXPERIMENTAL
Intervention: Presentation of pertinent information in immediate decision contexts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Absence of pertinent information
Number of subjects: 0
Study: 11830911

Group type: EXPERIMENTAL
Intervention: Active ionic toothbrush with an active battery
Number of subjects: 52

Group type: COMPARATOR
Intervention: Inactive ionic toothbrush with an inactive battery
Number of subjects: 52
Study: 8519720

Group type: EXPERIMENTAL
Intervention: INB+ (Intercostal nerve block with bupivacaine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: INB- (Intercostal nerve block with saline)
Number of subjects: 20
Study: 1960255

Group type: EXPERIMENTAL
Intervention: Triclosan-fluoride dentifrice (1100 ppm F, NaF)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Positive control (1100-ppm F, NaF)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 15
Study: 6763833

Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Self recordings of BP
Number of subjects: 48
Study: 30248365

Group type: EXPERIMENTAL
Intervention: Taurine (TAU) supplementation, single dose, dosage not specified
Number of subjects: 0
Study: 27552212

Group type: EXPERIMENTAL
Intervention: Compressive garment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Regular sports shorts
Number of subjects: 27
Study: 25943374

Group type: EXPERIMENTAL
Intervention: jack-knife position
Number of subjects: 104

Group type: COMPARATOR
Intervention: lithotomy position
Number of subjects: 104
Study: 23575698

Group type: EXPERIMENTAL
Intervention: Warm-up exercises on a laparoscopic trainer immediately before surgery
Number of subjects: 237

Group type: COMPARATOR
Intervention: No warm-up exercises (Control)
Number of subjects: 237
Study: 21293156

Group type: EXPERIMENTAL
Intervention: ACEi and/or ARB therapy; 94% of patients had prior therapy with ACEi and/or ARB at the time of screening.
Number of subjects: 2303

Group type: COMPARATOR
Intervention: No specific control intervention mentioned; control group not explicitly defined.
Number of subjects: 2303
Study: 19222588

Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 2068

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2068
Study: 17768289

Group type: EXPERIMENTAL
Intervention: Spectral Gradient Acoustic Reflectometry (SGAR)
Number of subjects: 786

Group type: COMPARATOR
Intervention: Tympanometry
Number of subjects: 786
Study: 15067791

Group type: EXPERIMENTAL
Intervention: Walking 3 days/week at 65% of target heart rate reserve
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Walking 5 days/week at 65% of target heart rate reserve
Number of subjects: 0
Study: 12825328

Group type: EXPERIMENTAL
Intervention: Exercise group (Ex, n = 18) underwent simple, progressive lower body resistance exercises, 3 times/week for 10 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Exercise group (Ex, n = 18)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (Con, n = 7) maintained usual daily activities
Number of subjects: 25
Study: 10479220

Group type: EXPERIMENTAL
Intervention: High intake of vegetables and fruits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consumption of vegetables and fruits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental dietary studies in humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple-arm trials, randomized crossover studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single dose to years of treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary control methods
Number of subjects: 0
Study: 7741542

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50 micrograms/g) applied twice daily for up to 12 weeks
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50 micrograms/g)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (vehicle of calcipotriol ointment)
Number of subjects: 67
Study: 2202789

Group type: EXPERIMENTAL
Intervention: Postoperative fluorouracil (5‐FU) and heparin administered via the portal vein
Number of subjects: 1158

Group type: COMPARATOR
Intervention: No further treatment following curative resection
Number of subjects: 1158
Study: 7275458

Group type: EXPERIMENTAL
Intervention: 80 kcal VLCD (17 g protein)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 180 kcal VLCD (40 g protein)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 80/180 kcal VLCD (80 kcal for 1st and 2nd week, 180 kcal for 3rd and 4th week)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Mixed VLCD (80 kcal for 1st and 2nd week, 180 kcal with 17 g protein + 25.5 g CHO for 3rd and 4th week)
Number of subjects: 25
Study: 11850494

Group type: EXPERIMENTAL
Intervention: 90Y‐ibritumomab tiuxetan
Number of subjects: 0
Study: 29439395

Group type: EXPERIMENTAL
Intervention: Probiotic-mixture (Vivomixx®, Visbiome®, DeSimone Formulation®)
Number of subjects: 53
Study: 28010833

Group type: EXPERIMENTAL
Intervention: Cervi Pantotrichum Cornu pharmacopuncture
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rehmannia glutinosa pharmacopuncture
Number of subjects: 40
Study: 23911209

Group type: EXPERIMENTAL
Intervention: Intraoperative regional cerebral oxygen saturation (rSO2) monitoring with active display and Murkin treatment intervention protocol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interventional group (rSO2 monitoring)
Number of subjects: 40
Study: 22093485

Group type: EXPERIMENTAL
Intervention: Intensive dietary therapy (dietary advice six times during pregnancy)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intensive dietary therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Close follow-up group (control)
Number of subjects: 54
Study: 19934619

Group type: EXPERIMENTAL
Intervention: Elevated parathyroid hormone (PTH) > or = 62 ng/L (IV-quartile)
Number of subjects: 514
Study: 18662417

Group type: EXPERIMENTAL
Intervention: Specialized nursing intervention addressing psychological and physical care post-surgery
Number of subjects: 145
Study: 15673874

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 40 mg IM and IV lidocaine 3 mg . kg(‐1) . h(‐1) (group DM+L)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 40 mg IM (group DM)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IV lidocaine 3 mg . kg(‐1) . h(‐1) (group L)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chlorpheniramine maleate (CPM) 20 mg IM and IV normal saline (N/S) (group C)
Number of subjects: 100
Study: 12771835

Group type: EXPERIMENTAL
Intervention: Standard design with a fixed polyethylene bearing
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Design with a mobile bearing
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: New design with a spherical medial femoral condyle with a fixed bearing
Number of subjects: 22

Group type: COMPARATOR
Intervention: Meniscal design (not explicitly named as control)
Number of subjects: 22
Study: 11800105

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using infrared diode laser (GaAlAs) 830 nm continuous wave and HeNe 632.8 nm combined with diode laser 904‐nm pulsed wave
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 74
Study: 8649560

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) combined with azathioprine 2 mg/kg, performed once a week for 4 weeks and thereafter every second week for 20 weeks (14 treatments)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) combined with azathioprine 2 mg/kg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control period (no plasma exchange)
Number of subjects: 11
Study: 1500744

Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV cocultivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma p24 antigen
Number of subjects: 0
Study: 6512000

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 0
Study: 30878174

Group type: EXPERIMENTAL
Intervention: Curvilinear supine position
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (standard positioning)
Number of subjects: 104
Study: 30178484

Group type: EXPERIMENTAL
Intervention: Functional Tactile Object Recognition Test (fTORT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Treatment group (n=6)
Number of subjects: 28
Study: 27372844

Group type: EXPERIMENTAL
Intervention: tDCS (n=33)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MHF-tPCS (n=30)
Number of subjects: 100

Group type: COMPARATOR
Intervention: sham-tDCS (n=37)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MHF-tPCS
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 100

Group type: COMPARATOR
Intervention: sham-tDCS
Number of subjects: 100
Study: 25241756

Group type: EXPERIMENTAL
Intervention: Yoga training (YT)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Physical exercise (PE)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 309
Study: 22526196

Group type: EXPERIMENTAL
Intervention: QUIXIL® fibrin sealant (2 ml)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no QUIXIL®)
Number of subjects: 24
Study: 20488759

Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 179

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: metoclopramide
Number of subjects: 179